Voyager Acquisition Corp. (VACHW)

NASDAQ: VACHW · Real-Time Price · USD · Warrants
0.1407
+0.0303 (27.45%)
Apr 17, 2026, 4:00 PM EDT - Market closed
Market Cap407.33M +27.1%
Revenue (ttm)n/a
Net Income8.99M +117.1%
EPS0.28 +10.8%
Shares Out 31.63M
PE Ratio45.31
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume200,401
Open0.1200
Previous Close0.1104
Day's Range0.1200 - 0.1608
52-Week Range0.0501 - 0.3544
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About VACHW

Voyager Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the healthcare or healthcare related sectors. Voyager Acquisition Corp. was incorporated in 2023 and is based in Brooklyn, New York.

Sector Financials
Founded 2023
Country United States
Stock Exchange NASDAQ
Ticker Symbol VACHW
Full Company Profile

News

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

BROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the “Company”) held the general meeting on March 12, 2026 and approv...

5 weeks ago - GlobeNewsWire

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the “Company”) today announced that holders of 25,217,315 of the Com...

5 weeks ago - GlobeNewsWire

VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.

VERAXA shareholders approve merger & issuance of new shares to Voyager. Both resolutions are prerequisites for the closing of the business combination.

6 weeks ago - GlobeNewsWire

VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology

Partnership combines Secarna's OligoCreator® platform with VERAXA's technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases Partnership combines Secarna'...

7 months ago - GlobeNewsWire

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp.,  a Cayman Islands exempt...

9 months ago - GlobeNewsWire

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors VERAXA Attending ASCO and BIO with...

11 months ago - GlobeNewsWire

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel...

11 months ago - GlobeNewsWire